Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Yкраї́нська
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
  • SCTIMST
  • Annual Reports
  • Patents
  • Communities & Collections
  • All of DSpace
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Yкраї́нська
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "RADHAKRISHNAN, K"

Now showing 1 - 1 of 1
Results Per Page
Sort Options
  • Item
    TREATMENT OF PARKINSONS-DISEASE
    (NEUROLOGY INDIA, 1995) VIJAYARAGHAVAN, A; RADHAKRISHNAN, K
    Inspite of extensive research the ideal drug therapy for idiopathic Parkinson's disease (PD) and its optimal timing remain uncertain. Levodopa still is the mainstay of therapy for PD, Little evidence exists to incriminate early institution of levodopa therapy in the development of motor fluctuations and dyskinesias in PD, These complications are probably a consequence of disease progression, and resultant inability to synthesize and store dopamine, and buffer the variability in dopamine availability, Therefore, withholding levodopa therapy until late stage of the disease is not warranted. Dopa agnoists provide only a short-term benefit, The neuroprotective effect of selegeline remains to be established, There is not enough evidence to justify the current practice of initiating treatment for PD patients with expensive polypharmacy. Research into the development of inexpensive levodopa containing preparations needs to be encouraged.
  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback